Immortal time bias in observational studies of drug effects

被引:412
作者
Suissa, Samy
机构
[1] McGill Univ, Ctr Hlth, McGill Pharmaceut Res Unit, Montreal, PQ, Canada
[2] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada
[3] McGill Univ, Dept Med, Montreal, PQ, Canada
关键词
biases; cohort studies; drug effectiveness; databases; epidemiology;
D O I
10.1002/pds.1357
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose Recent observational studies suggest that various drugs are remarkably effective at reducing morbidity and mortality. These cohort studies used a flawed approach to design and data analysis which can lead to immortal time bias. We describe the bias from 20 of these studies and illustrate it by showing that unrelated drugs can be made to appear effective at treating cardiovascular disease (CVD). Methods The illustration used a cohort of 3315 patients, with chronic obstructive pulmonary disease (COPD), identified from the Saskatchewan Health databases, hospitalised for CVD and followed for up to a year. We used the biased approach to assess the effect of two medications, namely gastrointestinal drugs (GID) and inhaled beta-agonists (IBA), both unknown to be effective in CVD, on the risk of all-cause mortality. We also estimated these effects using the proper person-time approach. Results Using the inappropriate approach, the rates ratios of all-cause death were 0.73 (95%CI: 0.57-0.93), with IBA and 0.78 (95%CI: 0.61-0.99), with GID. These rate ratios became 0.98 (95%CI: 0.77-1.25) and 0.94 (95%CI: 0.73-1.20), respectively, with the proper person-time analysis. Conclusions Several recent observational studies used a flawed approach to design and data analysis, leading to immortal time bias, which can generate an illusion of treatment effectiveness. Observational studies, with surprising beneficial drug effects should be re-assessed to account for this source of bias. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:241 / 249
页数:9
相关论文
共 32 条
[1]   Intranasal steroids and the risk of emergency department visits for asthma [J].
Adams, RJ ;
Fuhlbrigge, AL ;
Finkelstein, JA ;
Weiss, ST .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (04) :636-642
[2]   Impact of inhaled antiinflammatory therapy on hospitalization and emergency department visits for children with asthma [J].
Adams, RJ ;
Fuhlbrigge, A ;
Finkelstein, JA ;
Lozano, P ;
Livingston, JM ;
Weiss, KB ;
Weiss, ST .
PEDIATRICS, 2001, 107 (04) :706-711
[3]  
[Anonymous], 2000, Encyclopedia of Epidemiologic Methods
[4]   Inhaled corticosteroids and hospitalisation due to exacerbation of COPD [J].
Bourbeau, J ;
Ernst, P ;
Cockcoft, D ;
Suissa, S .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (02) :286-289
[5]   Inhaled steroids and the risk of hospitalization for asthma [J].
Donahue, JG ;
Weiss, ST ;
Livingston, JM ;
Goetsch, MA ;
Greineder, DK ;
Platt, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (11) :887-891
[6]   N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease [J].
Gerrits, CMJM ;
Herings, RMC ;
Leufkens, HGM ;
Lammers, JWJ .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (05) :795-798
[7]   Statins and fracture risk [J].
Hennessy, S ;
Strom, BL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (14) :1888-1889
[8]   Statins and the risk of dementia [J].
Jick, H ;
Zornberg, GL ;
Jick, SS ;
Seshadri, S ;
Drachman, DA .
LANCET, 2000, 356 (9242) :1627-1631
[9]  
Klungel OH, 2002, ANN PHARMACOTHER, V36, P751
[10]   HMG-CoA reductase inhibitors and the risk of fractures [J].
Meier, CR ;
Schlienger, RG ;
Kraenzlin, ME ;
Schlegel, B ;
Jick, H .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (24) :3205-3210